Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care. Finding out whether these outcomes differ from those of other patients who have survived critical care will help to inform clinical practice and appropriate follow-up care.

Calendar on a computer screen

To date, over 12,000 patients have been treated on an Intensive Care Unit (ICU) in England, Wales and Northern Ireland for very severe COVID-19 disease. Around 60% of them have survived to leave hospital, after an average of 11 days of care. Scientists are not only unclear on the long-term effects of the disease itself; they also know very little about the impact of a stay in ICU on these patients.

Before the COVID-19 outbreak, the Oxford Critical Care Research Group (CCRG) had developed efficient approaches to systematically follow up ICU patients over the long term. Their approach involves linking data from the Case Mix Programme, to which ICUs report, to multiple other routine healthcare data sources, through NHS Digital.

This new study funded by The University of Oxford’s COVID-19 Research Response Fund will look at key six-month health outcomes in patients who survived severe COVID-19 in England. It will provide timely data on additional risks faced by survivors that might be mitigated by specialist or community follow-up. It is hoped that this initial study will lead to further research on longer-term follow-up, with a wider range of patient outcomes.

Book photo created by rawpixel.com - www.freepik.com

Similar stories

European Platform for Neurodegenerative Diseases launches repository of cohorts for researchers

The new Cohort Catalogue will facilitate discovery of over 60 neurodegeneration research cohorts from 17 countries across Europe

Two NDCN students join BNA Scholars Programme

The British Neuroscience Association Scholars Programme was launched in 2021 with a view to improving equality, diversity and inclusion in neuroscience.

Researchers win UK Dementia Research Institute Grand Challenge Award to identify early signs of Alzheimer's

The MRC Brain Network Dynamics Unit has received funding for a multi-year research partnership designed to advance the understanding of early changes to the operations of brain circuits in Alzheimer's disease.

Ophthalmology Conference in Kyiv

On 21 February, Robert MacLaren organised a one-day ophthalmology conference in Kyiv together with Dr Andrii Ruban, President of the Ukrainian Vitreoretinal Society.

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.